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A Purified Capsular Polysaccharide Markedly Inhibits Inflammatory
Response during Endotoxic Shock
M. Piccioni,a C. Monari,a S. Kenno,a E. Pericolini,a E. Gabrielli,a D. Pietrella,a S. Perito,a F. Bistoni,a T. R. Kozel,b A. Vecchiarellia
Microbiology Section, Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Perugia, Italya; Department of Microbiology and
Immunology, University of Nevada, School of Medicine, Reno, Nevada, USAb
Capsular material of the opportunistic fungus Cryptococcus neoformans is composed mainly of a polysaccharide named glucu-
ronoxylomannan (GXM). In this study, the effects of GXMwere analyzed in an in vivo experimental system of lipopolysaccha-
ride (LPS)-induced shock. Endotoxic shock was induced in mice by a single intraperitoneal injection of LPS from Escherichia
coli. GXM treatment reduced the mortality of mice at early stages. Mice treated with LPS alone showedmarkedly increased
plasma levels of tumor necrosis factor alpha (TNF-), interleukin-1 (IL-1), and IL-6, whereas mice that were also treated with
GXM showed significantly lower plasma levels of these cytokines. This effect was related to a marked suppression of Akt and
IB activation. Importantly, the inhibitory effect of GXM on proinflammatory cytokine secretion was reproduced by treatment
with wortmannin, an inhibitor of the Akt transcription pathway. Our results indicate that GXM has a beneficial effect on endo-
toxic shock, resulting in a significant increase in the rate of survival by dampening the hyperinflammatory response.
The fungus Cryptococcus neoformans is the causative agent ofcryptococcosis and the only major fungal pathogen which
possesses a polysaccharide capsule (1). Capsular polysaccharides
are released into host tissues (2–5), where they exert numerous
deleterious effects on the host immune function (6–8). Glucuron-
oxylomannan (GXM) is the principal component of the capsular
material of C. neoformans, and it has been isolated from body
fluids of patients with cryptococcosis (9). We previously reported
that GXM inhibits proinflammatory cytokine production by mac-
rophages (10) and induces alteration of costimulatory molecule
expression (11) and apoptosis (11, 12).
These suppressive anti-inflammatory properties of GXM have
been exploited to obtain beneficial effects in an in vivo experimen-
tal model of rheumatoid arthritis, a pathology in which the in-
flammatory reaction is the critical issue (13).
Inflammatory shock following release of lipopolysaccharide
(LPS) from Gram-negative bacteria is a serious clinical concern.
In humans, immune responses to LPS result in the release of many
inflammatory cytokines from monocytes and macrophages, in
particular tumor necrosis factor alpha (TNF-), interleukin-1
(IL-1), and IL-6, which can cause fever, shock, organ failure, and
death (14, 15).
Toll-like receptor 4 (TLR4) is the central signaling receptor for
LPS in mammals (16). LPS binds to the TLR4 receptor complex,
consisting of soluble CD14 (sCD14) and MD2. This results in the
recruitment of the adaptor molecule MyD88. Phosphatidylinosi-
tol 3-kinase (PI3K), through association with MyD88 via an Akt-
dependent mechanism, is involved in NF-B activation (17).
Current knowledge on the structure and function of TLR4 has
opened up the possibility of developing new drug targets to fight
sepsis and other diseases associated with this signaling molecule
(18). Recently, direct antagonists of the LPS receptor TLR4 were
developed for treating sepsis (19–21), and various molecules in-
terfering with TLR4 expression or the TLR4-related intracellular
pathway have been proposed as new therapies able to weaken the
deleterious effects of an excessive host response. However, most of
these have not yet been exploited, and additional studies are re-
quired to confirm their expected action (22). Furthermore, TLR4-
blocking treatments (such as the TLR4 antagonist eritoran) are
still under investigation (23). This study therefore aimed to exam-
ine alternative options for curing sepsis.
Given that GXM is able to reduce LPS-induced inflammatory
cytokines in vitro (24) and to inhibit signal transduction triggered
by TLR4 (11), the aim of this study was to evaluate the possible
effect of GXM treatment on LPS-induced endotoxic shock and the
related signaling that involves the MyD88/Akt/NF-B pathway.
MATERIALS AND METHODS
Ethics statement. All animal experiments adhered to European Union
directive 2010/63. Experiments were performed according to the guide-
lines of the European Convention for the Protection of Vertebrate Animals
Used for Experimental andOther Scientific Purposes (25). The protocol was
approved by the Perugia University Ethics Committee. All efforts were
made to minimize suffering.
Reagents andmedia.RPMI 1640 with L-glutamine was obtained from
Gibco BRL (Paisley, Scotland, United Kingdom). Fetal calf serum (FCS),
penicillin, and Dulbecco’s modified Eagle medium (DMEM) were pur-
chased from the American Type Culture Collection (ATCC) (Manassas,
VA). A purified mouse monoclonal antibody to pAkt (pS472/pS473)
(clone 104A282) was purchased from BD Pharmingen (BD Biosciences,
Franklin Lakes, NJ). A rabbit polyclonal antibody to Akt was purchased
from Cell Signaling Technology (Beverly, MA). A goat polyclonal anti-
body to pIB (Ser-32), rabbit polyclonal antibodies to IB, actin (H-
300), and MyD88 (HFL-296), and horseradish peroxidase (HRP)-linked
rabbit polyclonal anti-goat IgG were obtained from Santa Cruz Biotech-
nology (Santa Cruz, CA). A rabbit polyclonal antibody to pSHIP (Tyr
pY120), a mouse monoclonal antibody to SHIP, and a goat polyclonal
antibody to FcRIIB (Ala46/Pro217) were purchased from StemCell
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Technologies (Vancouver, Canada), Exbio Antibodies (Czech Republic),
and R&D Systems (Minneapolis, MN), respectively. HRP-linked goat
polyclonal anti-rabbit IgG and HRP-linked goat polyclonal anti-mouse
IgG were purchased from Bio-Rad Laboratories (Hercules, CA). Cyanine
3 (Cy3)-conjugated rabbit polyclonal anti-goat IgG was purchased from
Chemicon International (Temecula, CA). Mammalian protein extraction
reagent (M-PER) and Restore Western stripping buffer were obtained
from Pierce (Rockford, IL). An Immun-Star HRP chemiluminescence kit
was purchased from Bio-Rad Laboratories (Hercules, CA). Lipopolysac-
charides from Escherichia coli O55:B5 and wortmannin from Penicillium
funiculosum were purchased from Sigma-Aldrich (St. Louis, MO). All
media used for cell culture were negative for endotoxin as detected by
Limulus amebocyte lysate assay (Sigma-Aldrich), which had a sensitivity
of approximately 0.05 to 0.1 ng of Escherichia coli lipopolysaccharide
per ml.
Mice. Eleven- to 12-week-old male C57BL/6J mice were obtained
from Harlan Nossan Laboratories (Milan, Italy) and maintained under
specific-pathogen-free conditions in the animal care facility of the Uni-
versity of Perugia (Perugia, Italy).
Cryptococcal polysaccharide. Glucuronoxylomannan was isolated
from the culture supernatant fluid of a serotype A strain (CN6) grown in
liquid synthetic medium in a gyratory shaker at 30°C for 4 days, as previ-
ously described (26). GXM was isolated by differential precipitation with
ethanol and hexadecyltrimethyl ammonium bromide (Sigma-Aldrich) as
previously described (27).
Endotoxic shock and GXM treatment. Endotoxic shock was induced
in 11- to 12-week-old male C57BL/6J mice by a single injection of LPS
from Escherichia coli O55:B5. The GXM dosage (100 g/mouse) was de-
termined based on our previous experience with experimental models
(28), and the number of injections was based on the results of preliminary
experiments. LPS and/or GXM was given as a single dose intraperitoneally
(i.p.) in 200 l of sterile saline solution. For survival experiments, a lethal
dose of LPS was used (1.5 mg/mouse) (29). Mice were randomly divided
into five groups (5 mice/group): (i) control (200 l of sterile saline solu-
tion/mouse), (ii) LPS, (iii) GXM, (iv) LPS plus GXM (GXM administra-
tion 15 min after LPS injection), and (v) GXM plus LPS (GXM adminis-
tration 60 min before LPS injection). The survival rate of mice was
monitored for up to 5 days.
To study GXM’s effects on cytokine production and intracellular sig-
nals, a sublethal dose of LPS was used (0.6 mg/mouse) (30). Mice were
randomly divided into eight groups (5 mice/group): (i) control (200l of
sterile saline solution/mouse), (ii) LPS, (iii) GXM, (iv) LPS plus GXM
(GXM administration 15 min after LPS injection), (v) GXM plus LPS
(GXM administration 60 min before LPS injection), (vi) wortmannin
plus LPS (i.p. injection of 0.3 mg of wortmannin per kilogram of body
weight 90 min before injection of LPS), (vii) wortmannin plus GXM (i.p.
injection of 0.3 mg of wortmannin per kilogram of body weight 90 min
before injection of GXM), and (viii) wortmannin plus LPS plus GXM (i.p.
injection of 0.3 mg of wortmannin per kilogram of body weight 90 min
before injection of LPS and subsequent injection of GXM 15 min later).
TNF-, IL-6, IL-1, and IL-10 determinations. Spleens and lymph
nodes were recovered, homogenized, filtered by use of a Cell Strainer
device (BD Biosciences), and centrifuged. Supernatant fluids were steril-
ized by passage through a Millipore filter (0.45-m pore size). Serum was
isolated from blood. Sera and supernatant fluids were stored at 80°C
until analysis. For in vitro determination of TNF-, RAW264.7 cells (5
106/ml) were treated with LPS for 30 min and then with GXM (100g/ml)
for 1 h at 37°C with 5% CO2, and the supernatants were collected. Cyto-
kine levels were determined by the use of commercial enzyme-linked im-
munoassay kits (BioLegend) according to the manufacturer’s recommen-
dations.
Western blotting for pAkt, pIB, and MyD88. For Western blot-
ting, spleens were recovered, homogenized, filtered by use of a Cell
Strainer device (BD Biosciences), and centrifuged. The cell pellet was
treated with hypotonic saline buffer to lyse erythrocytes, and then 30 
106 cells of each sample were subjected to protein extraction with M-PER
in the presence of protease inhibitors (Sigma-Aldrich) and phosphatase
inhibitors (Sigma-Aldrich).
Protein concentrations were determined with a bicinchoninic acid
(BCA) protein assay reagent kit (Pierce). The lysates (20 g of each sam-
ple) were separated by sodium dodecyl sulfate-10% polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred to a nitrocellulose mem-
brane (Pierce) for 1 h at 100 V in a blotting system (Bio-Rad) for Western
blot analysis.
Membranes were placed in blocking buffer (3% nonfat dried milk)
and incubated overnight at 4°C with a mouse monoclonal antibody to
pAkt (S472/S473) (1:500), a goat polyclonal antibody to pIB (Ser32)
(1:200), or a rabbit polyclonal antibody to MyD88 (HFL-296) (1:200).
Immunoblotting with rabbit polyclonal antibodies to IB (1:200), Akt
(1:1,000), and actin (H-300) (1:200) was used as an internal loading con-
trol to ensure equivalent amounts of protein in each lane. Detection was
achieved using appropriate HRP-linked secondary antibodies followed by
an Immun-Star HRP chemiluminescence kit (Bio-Rad).
Immunoreactive bands were visualized and quantified by use of
Chemidoc instruments (Bio-Rad).
RAW264.7 cell line. The murine macrophage cell line RAW264.7 was
obtained from the ATCC. Cells were maintained in DMEM with L-glu-
tamine supplemented with 10% FCS and antibiotic (100 U/ml penicillin)
at 37°C and 5% CO2.
Western blotting for pSHIP and pIB. RAW264.7 cells (107) were
incubated in DMEM plus 10% FCS in the presence or absence of a goat
polyclonal antibody to FcRIIB (Ala46/Pro217) (0.5g/ml) for 30 min at
4°C for pSHIP determination and in the presence or absence of LPS (10
g/ml) for 30 min at 37°C with 5% CO2 for pIB determination. The
cells of each sample were washed once with phosphate-buffered saline
(PBS) and incubated in the presence or absence of GXM (100 g/ml) in
DMEM plus 10% FCS for 30 min for pSHIP or 15 min for pIB, at 37°C
with 5% CO2. The cell pellets were subjected to protein extraction with 20
l of mammalian protein extraction reagent in the presence of protease
inhibitors (Sigma-Aldrich) and phosphatase inhibitors (Sigma-Aldrich).
The lysates (60g of each sample for pSHIP and 30g of each sample for
pIB) were separated as described above, and membranes were incu-
bated overnight at 4°C with a rabbit polyclonal antibody to pSHIP (Tyr
pY120) (1:2,500). Immunoblotting with a mouse monoclonal antibody to
SHIP (1:2,500) was used as an internal loading control to ensure equiva-
lent amounts of protein in the lanes. Detection and visualization of im-
munoreactive bands were obtained as described above.
Flow cytometry for pIB. For flow cytometry analysis, RAW264.7
cells (1  106/ml) were incubated in DMEM plus 10% FCS in the
presence or absence of LPS (10 g/ml). After 30 min of culture, the
cells were incubated alone or with GXM (100 g/ml) for 15 min at
37°C with 5% CO2. After incubation, cells were collected by centrifu-
gation, fixed in 2% formalin in PBS for 10 min at room temperature,
and permeabilized with ice-cold methanol (500 l/106 cells) for 10
min at 4°C. Cells were washed twice in PBS containing 1% bovine
serum albumin (BSA) and stained with a goat polyclonal antibody to
pIB (1:50) in PBS containing 1% BSA for 30 min at room temper-
ature. After incubation, cells were washed twice, stained with Cy3-
conjugated rabbit polyclonal anti-goat IgG (1:100), and washed twice
more in PBS-1% BSA, and then 5,000 events were analyzed using a
FACSCalibur flow cytometer (BD Biosciences). Autofluorescence was
assessed by using untreated cells. Data are expressed as mean fluores-
cence intensities (MFI) of labeled cells.
Statistical analysis. Data are reported as means  standard errors of
the means (SEM) for 3 to 5 replicate experiments. Data were evaluated by
one-way analysis of variance (ANOVA). Post hoc comparisons were made
with Bonferroni’s test. The log rank test was applied to the survival data. A
P value of	0.05 was considered significant.
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RESULTS
GXM improves survival of endotoxemicmice.Given that Gram-
negative infection and administration of LPS in humans and ani-
mals result in a systemic inflammatory response (28, 31) which
partially mimics features of early sepsis, we tested the capacity of
GXM to influence the course of LPS-induced sepsis (32). Healthy
mice were treated with 100 g of GXM 60 min before or 15 min
after LPS administration. A significant (P	 0.05) increase in sur-
vival of GXM-treated mice compared to non-GXM-treated mice
was observed. The survival rate rose from 20% to 60% (Fig. 1A).
As evidenced in Fig. 1B, the LPS-treated mice died of endotoxic
shock within 2 days. A significant increase of median survival time
(MST) was observed in GXM-treated mice. Indeed, soon after LPS
administration, tremor, diarrhea, crouching gait, immobility, and
piloerection were observed, but the mice treated with GXM
showed either no symptoms or much less severe symptoms than
those of mice not treated with it. In addition, the mice sacrificed 6
h after LPS administration showed evident splenomegaly, with a
concomitant increase in the total number of spleen cells (data not
shown). In contrast, in the spleens of GXM-treated mice, no gross
pathological abnormalities were observed, and the total number
of splenocytes was not greater than that in saline-treated mice
(data not shown).
The dose of GXM (100g/mouse) was extrapolated from pre-
vious in vivo experiments which demonstrated that this was the
appropriate dose to inhibit proinflammatory cytokine secretion
and to positively influence septic arthritis and rheumatoid arthri-
tis, pathologies characterized by aberrant inflammatory responses
(33, 34). A lower dose of GXM (10 g/mouse) was also used, but
under this experimental condition, GXM did not affect the course
of LPS-induced sepsis.
GXM reduces LPS-induced IL-1, TNF-, and IL-6 levels
and increases IL-10 levels. LPS triggers the release of many in-
flammatory cytokines, and it has been implicated in lethal septic
shock (14). Therefore, we analyzed IL-1 secretion by splenic
macrophages from mice treated with LPS and GXM. The kinetic
evaluation of IL-1 levels from supernatant fluids from spleens
showed a large increase in IL-1 secretion 1 h after LPS treatment,
followed by a gradual decrease. GXM treatment of mice receiving
LPS produced a significant downregulation of IL-1 at 1 h and 6 h
postadministration (Fig. 2A). We also evaluated the kinetics of the
IL-1 response in sera from the same animals. The results showed
a significant decrease in IL-1 levels in the sera of mice treated
with LPS and GXM compared to the sera of LPS-treated mice
throughout the period of observation (1 h, 6 h, and 24 h after LPS
challenge) (Fig. 2B).
The kinetics of TNF- production in spleens and sera showed
that in LPS-GXM-treated mice, TNF- subsided more quickly
than it did in mice treated with LPS alone, and significant de-
creases (P 	 0.05) of TNF- levels were observed in the spleens
and sera after 24 h (Fig. 2C and D).
IL-6 was also tested in our experimental system. The results
showed significant (P	 0.05) reductions of IL-6 levels in spleens
and sera (Fig. 2E and F) of LPS- and GXM-treated mice with
respect to those of mice treated with LPS only. This effect was
evident 1 h after LPS treatment, but no such effect was observed
after 6 and 24 h.
In addition, IL-10, a prototypical anti-inflammatory cytokine,
was tested. The results showed that IL-10 levels in the group
treated with LPS only subsided faster than those in the LPS-GXM-
treated group. This was observed in the spleens (Fig. 2G) and sera
(Fig. 2H) 24 h after GXM treatment.
The ratio of proinflammatory to anti-inflammatory cytokines
was analyzed, and we observed that in sera and spleens of LPS-
GXM-treated mice, there were 8- and 2-fold decreases in TNF-,
respectively. Furthermore, in sera and spleens of LPS-GXM-
treated mice, there were 2- and 1.5-fold increases in IL-10, respec-
tively.
GXM produces inhibition of LPS-induced pAkt and pIB.
The PI3K-Akt pathway (via TRAF6) may participate in NF-B
activation induced by LPS through TLR4 stimulation (35). As a
consequence, we examined the role of the PI3K-Akt pathway in
our experimental system, as well as whether GXM was able to
regulate LPS-induced Akt expression. We also used wortmannin,
which is a pharmacologic inhibitor of the PI3K-Akt pathway. This
compound has been used extensively to analyze the role of Akt in
the regulation of different intracellular pathways (36, 37). Mice
were treated with wortmannin (0.3 mg/kg of body weight) 90 min
before LPS administration, following a previously reported pro-
cedure (23). Mice were also treated with 100 g of GXM before
FIG 1 GXM improves survival of endotoxemic mice. (A) Mice were treated with LPS (1.5 mg/mouse) and/or GXM (100 g/mouse) 60 min before or 15 min
after LPS treatment and were monitored for death for up to 5 days, and survivors were then euthanized. Data are from three independent experiments. The
percentage of survival was evaluated according to the log rank test, and the difference among experimental groups was significant. (B) Table reporting the mean
survival time (MST) in days and the number of dead mice/total number of animals tested (cumulative results for all three experiments) (D/T). *, P 	 0.05
(LPS-plus-GXM-treated versus LPS-treated mice).
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(60 min) and after (15 min) LPS administration, and Akt activa-
tion was determined 24 h after LPS administration. The results
(Fig. 3A) showed that both wortmannin and GXM treatment pro-
duced a strong inhibition of LPS-induced Akt activation, regard-
less of the time of GXM administration. The effects of wortman-
nin and GXM treatment on LPS-induced MyD88 recruitment
were evaluated. The results (Fig. 3B) showed that both GXM and
wortmannin treatment significantly (P 	 0.05) reduced LPS-in-
duced MyD88 recruitment. The effect of wortmannin on MyD88
was consistent with previous results showing that wortmannin
FIG 2 GXM induces regulation of IL-1, TNF-, IL-6, and IL-10 production in spleens and sera of endotoxemic mice. Mice were treated with sterile saline or
with LPS (0.6 mg/mouse) and/or GXM (100 g/mouse) 15 min after LPS treatment. IL-1 (A and B), TNF- (C and D), IL-6 (E and F), and IL-10 (G and H)
levels in supernatant fluids from spleens and in sera were determined by enzyme-linked immunosorbent assay (ELISA) 1 h, 6 h, and 24 h after LPS treatment.
Values represent the means and SEM for five separate experiments. *, P	 0.05 (LPS-plus-GXM-treated versus LPS-treated mice).
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reduced the PI3K activity in anti-MyD88 immunoprecipitates
(17).
The major players involved in eliciting the functional effects of
LPS are activated through the NF-B and PI3K-Akt pathways.
These pathways regulate the balance between cell viability and
inflammation. Thus, 24 h after LPS administration, we analyzed
the activation of NF-B by assessment of LPS-induced pIB in
splenic macrophages of both mice treated with and mice not
treated with GXM. The results showed that in both groups, LPS-
induced IB activation was markedly suppressed. Similar results
were obtained after wortmannin administration (Fig. 4).
GXM dampens TNF- production in spleens, sera, and
lymph nodes of LPS-treatedmice. Finally, TNF-, the prototype
of proinflammatory cytokines, was evaluated (24 h after LPS ad-
ministration) in the spleens, sera, and local lymph nodes of mice
treated with LPS in the presence or absence of GXM and wort-
mannin. The results (Fig. 5) show that GXM treatment signifi-
cantly (P 	 0.05) inhibited LPS-induced TNF- production by
the spleen (Fig. 5A), serum (Fig. 5B), and lymph nodes (Fig. 5C),
regardless of the time of GXM treatment. Wortmannin treatment
also inhibited LPS-induced TNF- secretion.
GXM treatment affects LPS-induced IB activation and
TNF- production in RAW264.7 cells. Given that GXM’s inhib-
itory effects are thought to be via SHIP activation following GXM
binding to FcRIIB, we performed experiments to evaluate
whether the blockade of this interaction results in a modulation of
SHIP activation. The results reported clearly show that GXM is
able to induce SHIP activation and that this effect is completely
inhibited by blocking the interaction of GXM with FcRIIB (Fig.
6A). Furthermore, cells were treated with LPS in the presence or
absence of GXM, and then IB activation and TNF- produc-
tion were tested. The results reported in Fig. 6B show that there
was a significant decrease in IB activation in LPS-activated cells
treated with GXM, and this was observed through Western blot-
FIG 3 GXM treatment inhibits Akt and MyD88 recruitment in endotoxemic mice. Mice were treated as described in Materials and Methods and then were
sacrificed 24 h after LPS treatment. (A) Western blotting for pAkt. Optical densities of reactive bands were measured and normalized by the Akt density in the
same lane. Actin was used as a loading control. (B) Western blotting for MyD88. Optical densities of reactive bands were measured and normalized by the actin
density in the same lane. In both panels A and B, pAkt and MyD88 were quantified relative to the levels in saline-treated mice. Blots are representative of five
independent experiments with similar results. Bars represent the means and SEM for five experiments. *, P 	 0.05 (LPS-plus-GXM-treated or wortmannin
[WM]-treated mice versus LPS-treated mice).
FIG 4 GXM treatment inhibits LPS-induced IB activation. Mice treated as
described in Materials and Methods were sacrificed 24 h after LPS treatment,
and pIB levels were determined by Western blotting. The optical densities of
reactive bands were measured and normalized by the IB density in the same
lane. Actin was used as a loading control. The membrane is representative of
five independent experiments with similar results.
Piccioni et al.
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ting as well as cytofluorometric determination (MFI). This effect
occurred in conjunction with the significant inhibition of TNF-
secretion by these cells (Fig. 6B).
DISCUSSION
In this study, we demonstrated that injection of the capsular poly-
saccharide ofC. neoformans into mice with LPS-induced endotox-
emia significantly improved the rate of survival. This beneficial
effect was related to (i) inhibition of TNF- secretion by splenic
macrophages and a decrease of TNF- levels in serum, (ii) down-
regulation of IL-6 production by splenocytes and a decrease of
IL-6 levels in serum, (iii) decreased levels of IL-1 in supernatants
of splenic macrophages and in serum, (iv) a decrease of Akt acti-
vation, (v) blockade of IB activation, and (vi) marked inhibi-
tion of MyD88 recruitment.
In vivo treatment with GXM profoundly influenced proinflam-
matory cytokine release induced by LPS; in particular, a singular
kinetic profile for TNF- and IL-1was observed. Treatment with
GXM resulted in a significant decrease of IL-1 secretion from
splenocytes. This decrease was observed 1 h after LPS injection
and was still evident after 6 h; at 24 h, the IL-1production rapidly
returned to the baseline level. The determination of IL-1 levels in
serum showed that the levels of this cytokine were consistently
lower than those observed in the supernatants of splenocytes, and
GXM had a downregulatory effect which was still observed 24 h
after LPS challenge. It is plausible that while the results obtained
from ex vivo cells are indicative of a compartmentalized immune
response in the spleen, the effect of GXM treatment observed in
the serum accounts for the sum of events that collectively occur in
vivo. In our opinion, the immunoinhibitory activity of GXM is a
determinant for survival. It is conceivable to suppose that the ma-
jor mechanism is through GXM binding to FcRIIB, with conse-
quent SHIP activation and inhibition of pAkt. This could account
for the beneficial effect of GXM in the two situations, i.e., given
either before or after LPS. A downregulatory role of SHIP in con-
trolling Akt activation has in fact been reported previously (38). It
has also been reported that GXM is able to bind to TLR4 (39, 40),
and it is possible that it competes for LPS binding to pattern rec-
ognition receptors (PRRs). However, the inhibitory effect of
GXM, observed when it was given both before and after LPS, sug-
gests that this possible competition does not play an important
role.
Previous studies have suggested that IL-6 serves as both a
marker and a mediator of the severity of sepsis (41). Several re-
ports indicate that plasma levels of IL-6 may be used as a diagnos-
tic marker for the presence of bacteremia (42). GXM treatment
decreased IL-6 levels in serum and in supernatants from spleno-
cytes soon after LPS injection, and this effect was subsequently
lost.
Conversely, GXM affected TNF- release late in the process.
Indeed, 24 h after LPS injection, there was a significant decrease in
serum TNF- levels that mirrored the decrease of TNF- secre-
tion by splenocytes. Indeed, the reductions of LPS-induced
TNF- observed in the spleen and serum after wortmannin and
GXM treatment were substantially greater than those in untreated
mice. This suggests that the observed levels of TNF- are compat-
ible with a therapeutic effect. This is consistent with previous re-
ports showing that controlled production of inflammatory cyto-
kines may be beneficial in several pathological settings (43–45)
and that, conversely, aberrant secretion results in deleterious ef-
fects (46, 47).
The different profiles of proinflammatory cytokine production
could imply their reciprocal regulation. In particular, there was a
decrease of IL-1 and IL-6 early on. The decrease of IL-1 was
prolonged, whereas the decrease of IL-6 was temporary, i.e., for 1
h after treatment.
The early decrease of IL-6 could be mediated directly by GXM
ligation to the immunoinhibitory receptor FcRIIB, but the pres-
FIG 5 GXM dampens TNF- production in spleens, sera, and lymph nodes of
LPS-treated mice. Mice treated as described in Materials and Methods were
sacrificed 24 h after LPS treatment. TNF- levels in spleen supernatant fluids
(A), sera (B), and lymph node supernatant fluids (C) were determined by
ELISA. Values represent the means and SEM for five separate experiments. *,
P 	 0.05 (LPS-plus-GXM-treated or wortmannin-treated mice versus LPS-
treated mice).
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ence of cytokines such as TNF-may promote the late secretion of
IL-6, as has been suggested before (48). However, the “cytokine
storm” involved in the hyperinflammatory response during endo-
toxemia is very complicated, and soluble molecules other than
TNF- are thought to play a role in the cytokine profiles observed
in our experimental system.
Significant inhibition of TNF- was observed when GXM was
administered before or after LPS challenge. It is possible that this
drastic decrease was a consequence of GXM-induced IL-10 pro-
duction. Indeed, we observed that GXM did not modulate IL-10
production 1 h or 6 h after LPS treatment, but it did induce a
consistent increase of IL-10 after 24 h, and this could account for
the strong decrease of TNF- observed 24 h after LPS treatment.
This is consistent with our previous results showing that GXM-
mediated inhibition of TNF- is mediated largely by induction of
anti-inflammatory cytokines such as IL-10 (24).
Previously, we demonstrated that GXM-mediated immuno-
suppression occurs via ligation to FcRIIB and subsequent SHIP
activation (24). The inflammatory process is driven by immuno-
pathological events such as the overproduction of various proin-
flammatory cytokines, including TNF-, IL-1, IL-6, and IL-12,
and inflammatory mediators (49). Production of these proinflam-
matory cytokines and inflammatory mediators is dependent upon
the activation of PRRs, such as TLR4 and TLR2, by microbial
ligands, including lipopolysaccharides (50). During activation of
PRRs, a series of intracellular signaling molecules, including mi-
togen-activated protein kinases (MAP kinases), are activated, re-
sulting in the upregulation of inflammatory gene expression by
transcription factors such as NF-B and activator protein 1
(AP-1) (30, 42, 43, 51).
Of the numerous signaling proteins that contribute to a large
number of signals, Akt (protein kinase B [PKB]) has a major role
in the regulation of metabolism, cell survival, motility, transcrip-
tion, and cell cycle progress (52, 53).
Akt is involved in regulating cell survival and controlling the
proliferation of many types of cancer (54). Members of the Akt
family are characterized by three distinct domains that play a crit-
ical role in the PI3K-dependent activation process. This involves
the generation of phosphatidylinositol (3,4,5)-trisphosphate
[PI(3,4,5)P3] from phosphatidylinositol (4,5)-bisphosphate
[PI(4,5)P2] and the subsequent recruitment and activation of Akt
(55). LPS binding to TLR4 may stimulate PI3K through its asso-
ciation with the TLR4-MyD88 signaling complex (via TRAF6)
(56). This transduction pathway involves Akt phosphorylation,
which leads to NF-B activation and consequently to proinflam-
matory cytokine gene expression (57). In our experimental sys-
tem, LPS administration produced a rapid and drastic increase of
Akt expression in splenocytes, whereas after GXM treatment, the
intensity of phospho-Akt became even weaker than that observed
in the unstimulated cells. This effect may be a consequence of
GXM ligation to FcRIIB, which, via the immunoreceptor ty-
rosine-based immunoinhibitory motif (ITIM), induces recruit-
ment of SHIP, which then converts PI(3,4,5)P3 into PI(4,5)P2.
Spontaneous activation of Akt in mouse splenocytes has in fact
been reported (58). Thus, the inhibitory effect of GXM can occur
regardless of LPS activation. Consistent with this hypothesis is the
anti-inflammatory effect of GXM we previously reported for an
experimental model of rheumatoid arthritis (34).
The inhibition of LPS-induced MyD88 activation strongly sug-
gests that GXM-mediated inhibition of LPS-induced signal trans-
duction is via the MyD88-dependent pathway and that the GXM
effect occurs via upstream signal regulation (Fig. 7).
This result is consistent with recent studies showing the mo-
lecular interactions among MyD88, PI3K, and TLR4 and suggest-
FIG 6 GXM induces SHIP activation by FcRIIB binding and inhibits LPS-induced inflammatory response in RAW264.7 cells. (A) RAW264.7 cells, pretreated
or not (NS) with FcRIIB (0.5g/ml) antibody, were incubated with GXM (100g/ml), washed, and subjected to Western blotting for pSHIP determination as
described in Materials and Methods. The blot is representative of three independent experiments with similar results. *, P 	 0.05 (anti-FcRIIB-plus-GXM-
treated versus GXM-treated mice). (B) RAW 264.7 cells were incubated in the presence or absence (NS) of LPS (10g/ml), and then GXM (100g/ml) was added
to determine IB activation and TNF- production. After incubation, the cells were washed and subjected to Western blotting or flow cytometry analysis for
pIB determination, as described in Materials and Methods. The blot is representative of three independent experiments with similar results. Bars represent the
means and SEM for three separate experiments. For TNF- evaluation, supernatants were collected and subjected to a specific ELISA. TNF- values represent the
means and SEM for five separate experiments. *, P	 0.05 (LPS-plus-GXM-treated versus LPS-treated mice).
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ing that signaling is achieved upon the simultaneous interaction of
multiple proteins that create a signaling platform which includes
MyD88 and Akt. As a consequence, the disruption of any one
interaction has a universal effect on the other protein-protein in-
teractions involved (56).
The inhibition of PIP3 directly reflects the strong decrease of
Akt activation and the suppression of IB activation. Indeed,
IB is one of the most crucial signaling kinases for activation of
NF-B, a transcription factor that is crucial for inflammation, cell
survival, and differentiation (30).
However, we cannot exclude the possibility that GXM-induced
inhibition of IB is the result of multiple effects of GXM on the
TLR4-mediated signaling pathway, including regulation of MAP
kinases. The GXM-induced inhibition of IB and the inability of
GXM to induce its activation are in contrast to results published
by Shoham et al. (39). However, this discrepancy could be related
to the different doses of GXM used: unlike Shoham et al., who
used 250 g/ml of GXM, we used 100 g/mouse of GXM in our
experiments. In addition, in our experimental system, GXM treat-
ment was performed in vivo, while Shoham et al. used an in vitro
model. These differences may explain the different results.
Because Akt has been considered a strong positive regulator of
various types of cancer and autoimmune diseases (59), an effective
and strong downregulation of Akt is considered a therapeutic ob-
jective for curing inflammatory diseases, particularly septic shock.
These results give evidence that GXM is a potent LPS antago-
nist and lacks agonistic activity in in vitro and in vivo systems,
making it a potentially effective therapeutic agent for treatment of
diseases caused by LPS.
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